Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study

NCT05219318 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT05219318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 23, 2023
Completion date
January 31, 2027
Enrollment
22 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

good or only one adverse prognostic factor intermediate risk per imdc score, metastatic renal cell carcinoma